Details
Stereochemistry | MIXED |
Molecular Formula | C20H37O7S.Na |
Molecular Weight | 444.558 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S([O-])(=O)=O
InChI
InChIKey=APSBXTVYXVQYAB-UHFFFAOYSA-M
InChI=1S/C20H38O7S.Na/c1-5-9-11-16(7-3)14-26-19(21)13-18(28(23,24)25)20(22)27-15-17(8-4)12-10-6-2;/h16-18H,5-15H2,1-4H3,(H,23,24,25);/q;+1/p-1
Molecular Formula | C20H37O7S |
Molecular Weight | 421.569 |
Charge | -1 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | Na |
Molecular Weight | 22.98976928 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Docusate, also known as docusate salts or dioctyl sulfosuccinate, prevents/relieves dry hard stool and thus is used to treat constipation. Results usually occurs 1 to 3 days after the first dose. In North America, docusate and a stimulant laxative such as sennosides are commonly used in bowel treatment protocols associated with institutionalized elderly and oncology treatments. A paucity of evidence is available to support the use of the stool softener docusate yet it continues to be prescribed in everyday clinical practice for the aforementioned populations. While the actual cost of docusate is low, additional costs associated with its administration (i.e. nursing time) and its widespread use can be significant. Docusate is absorbed into the bloodstream and excreted via the gallbladder after undergoing extensive metabolism. The effect of docusate may not necessarily be all due to its surfactant properties. Perfusion studies suggest that docusate inhibits fluid absorption or stimulates secretion in the portion of the small intestine known as the jejunum
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Separation of gamma-globulins from porcine plasma by reversed micellar extraction. | 2001 |
|
Catalytic activity of laccase hosted in reversed micelles. | 2001 |
|
Characterization and application of sodium di(2-ethylhexyl) sulfosuccinate and sodium di(2-ethylhexyl) phosphate surfactants as pseudostationary phases in micellar electrokinetic chromatography. | 2004 Dec 17 |
|
Shear-induced orientation of a rigid surfactant mesophase. | 2004 Jul 6 |
|
Transition from micelle to vesicle in aqueous mixtures of anionic/zwitterionic surfactants studied by fluorescence, conductivity, and turbidity methods. | 2005 Apr 15 |
|
Comparative studies on the micellization of sodium bis(4-phenylbutyl) sulfosuccinate and sodium bis(2-ethylhexyl) sulfosuccinate and their interaction with hydrophobically modified poly(acrylamide). | 2005 Apr 26 |
|
31P and 1h NMR as probes of domain alignment in a rigid crystalline surfactant mesophase. | 2005 Apr 26 |
|
Surfactant self-assembling in gas phase: electrospray ionization- and matrix-assisted laser desorption/ionization-mass spectrometry of singly charged AOT clusters. | 2005 Dec |
|
Dynamics of a membrane-bound tryptophan analog in environments of varying hydration: a fluorescence approach. | 2005 Dec |
|
Dynamics of water confined on a nanometer length scale in reverse micelles: ultrafast infrared vibrational echo spectroscopy. | 2005 Feb 11 |
|
Enhanced stabilization of reverse micelles by compressed CO2. | 2005 Feb 4 |
|
Investigation of micelle formation by fluorescence correlation spectroscopy. | 2005 Jul 14 |
|
Vibrational relaxation of azide in formamide reverse micelles. | 2005 Jul 7 |
|
Recycling nanoparticles stabilized in water-in-CO2 microemulsions for catalytic hydrogenations. | 2005 Mar 1 |
|
Reverse micelles dissolved in supercritical xenon: an NMR spectroscopic study. | 2005 Mar 3 |
|
Orientational dynamics of water confined on a nanometer length scale in reverse micelles. | 2005 May 1 |
|
On the temperature percolation in a w/o microemulsion in the presence of organic derivatives of chalcogens. | 2005 May 19 |
|
Real structure of formamide entrapped by AOT nonaqueous reverse micelles: FT-IR and 1H NMR studies. | 2005 Nov 10 |
|
Formation mechanism of conducting polypyrrole nanotubes in reverse micelle systems. | 2005 Nov 22 |
|
Efficient gene transfection using chitosan-alginate core-shell nanoparticles. | 2006 |
|
Nucleation and growth characteristics of a binary low-mass organogel. | 2006 Aug 15 |
|
Lipophilic porphyrin microparticles induced by AOT reverse micelles: a fluorescence lifetime imaging study. | 2006 Jan 20 |
|
Sensing behaviors of polypyrrole nanotubes prepared in reverse microemulsions: effects of transducer size and transduction mechanism. | 2006 Jul 27 |
|
Electrochemical extraction of proteins by reverse micelle formation. | 2006 Jun 20 |
|
Tuning the cooperativity of the helix-coil transition by aqueous reverse micelles. | 2006 Jun 22 |
|
Simultaneous determination of natural and synthetic estrogens by EKC using a novel microemulsion. | 2006 Nov |
|
Hydrogen bond lifetime dynamics at the interface of a surfactant monolayer. | 2006 Nov 23 |
|
An insight into the mechanism of protein separation by colloidal gas aphrons (CGA) generated from ionic surfactants. | 2006 Nov 7 |
|
[Chemotaxis as a method for testing of the biological effects of silver nanoparticles]. | 2006 Sep-Oct |
|
Study of confined 5-aza[5]helicene in ytterbium(III) bis(2-ethylhexyl) sulfosuccinate reversed micelles. | 2007 Apr 26 |
|
A novel composite: layered double hydroxides encapsulated in vesicles. | 2007 Dec 20 |
|
Ultrafast energy transfer in water-AOT reverse micelles. | 2007 Dec 27 |
|
Thiol-frozen shape evolution of triangular silver nanoplates. | 2007 Feb 13 |
|
Atomic force microscopy images of lyotropic lamellar phases. | 2007 Feb 7 |
|
Comparative study of the photophysical behavior of fisetin in homogeneous media and in anionic and cationic reverse micelles media. | 2007 May-Jun |
|
Site-specific hydration status of an amphipathic peptide in AOT reverse micelles. | 2007 Oct 23 |
|
The effect of changing the microstructure of a microemulsion on chemical reactivity. | 2007 Sep 11 |
|
On the possibility that cyclodextrins' chiral cavities can be available on AOT n-heptane reverse micelles. A UV-visible and induced circular dichroism study. | 2007 Sep 13 |
|
P450cam biocatalysis in surfactant-stabilized two-phase emulsions. | 2008 Apr 15 |
|
Micellization and synergistic interaction of binary surfactant mixtures based on sodium nonylphenol polyoxyethylene ether sulfate. | 2008 Feb 15 |
|
Fourier transform infrared spectroscopy of azide and cyanate ion pairs in AOT reverse micelles. | 2008 Jul 14 |
|
Design and control of patterns in reaction-diffusion systems. | 2008 Jun |
|
Optical sensor of anionic surfactants using solid-phase extraction with a lactone-form rhodamine B membrane. | 2008 Jun |
|
Fluorescence anisotropy of ionic probes in AOT reverse micelles: influence of water droplet size and electrostatic interactions on probe dynamics. | 2008 Jun 19 |
|
Modulation of dynamics and reactivity of water in reverse micelles of mixed surfactants. | 2008 Oct 16 |
|
Fine control over the morphology and structure of mesoporous silica nanomaterials by a dual-templating approach. | 2008 Oct 7 |
|
Characterization of multifunctional reverse micelles' interfaces using hemicyanines as molecular probes. I. Effect of the hemicyanines' structure. | 2009 Apr 2 |
|
Physico-chemical investigation of nanostructures in liquid phases: nickel chloride ionic clusters confined in sodium bis(2-ethylhexyl) sulfosuccinate reverse micelles. | 2009 Aug 1 |
|
Characterization of multifunctional reverse micelles' interfaces using hemicyanines as molecular probes. II: Effect of the surfactant. | 2009 May 14 |
|
Modulation of excited-state proton-transfer reactions of 7-hydroxy-4-methylcoumarin in ionic and nonionic reverse micelles. | 2009 May 14 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/docusate.html
Usual Adult Dose for Constipation:
Oral: 50 to 400 mg (using any of the salt forms) orally administered in 1 to 4 equally divided doses each day.
Rectal: 200 to 283 mg rectally administered as an enema once or twice. Alternative: 50 to 100 mg (docusate sodium liquid) added to a retention or flushing enema once a day.
Usual Pediatric Dose for Constipation:
Oral: less than 3 years: 10 to 40 mg (docusate sodium) orally divided in 1 to 4 doses. 3 to 6 years: 20 to 60 mg (docusate sodium) orally divided in 1 to 4 doses. 6 to 12 years: 40 to 150 mg (docusate sodium) orally divided in 1 to 4 doses. greater than 12 years: 50 to 400 mg (using any of the salt forms) orally administered in 1 to 4 equally divided doses each day.
Rectal: 3 to 18 years: 50 to 100 mg (docusate sodium liquid) added to a retention or flushing enema once a day. Alternative: 200 to 283 mg rectally administered as an enema once daily as needed for constipation.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11530185
It was evaluated the efficacy and toxicity of docusate against herpes simplex viruses (HSV). Docusate was effective in vitro against wild type and drug-resistant strains of HSV type 1 and 2 with EC(90-100) (effective concentration giving 90-100% virus yield reduction) of approximately 0.005% (w/v). The cytotoxicity profiles of docusate were time- and dose-dependent and thus associated with the frequency of use. Kinetics of inactivation examined by pre-mixing virus and drug in a time-course experiment demonstrated that docusate could reach its EC(90-100) within 30 min.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:35:33 GMT 2025
by
admin
on
Mon Mar 31 17:35:33 GMT 2025
|
Record UNII |
F05Q2T2JA0
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A06AG10
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-480
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
||
|
WHO-VATC |
QA06AG10
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
||
|
CFR |
21 CFR 172.520
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
||
|
JECFA EVALUATION |
INS-480
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
||
|
CFR |
21 CFR 172.810
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
||
|
CFR |
21 CFR 175.320
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
||
|
WHO-VATC |
QA06AA02
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
||
|
WHO-ATC |
A06AA02
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
||
|
NCI_THESAURUS |
C29699
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.4
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
||
|
DSLD |
3169 (Number of products:31)
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
531
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
C460182
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
m4716
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | Merck Index | ||
|
23673837
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
CHEMBL1477036
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
1224802
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
577-11-7
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
C29000
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
F05Q2T2JA0
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
F05Q2T2JA0
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
71722
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | RxNorm | ||
|
941
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
DTXSID8022959
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
209-406-4
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
3065
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
133817
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
SUB06348MIG
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
DBSALT001500
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
DIOCTYL SODIUM SULFOSUCCINATE
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
760404
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY | |||
|
100000092012
Created by
admin on Mon Mar 31 17:35:33 GMT 2025 , Edited by admin on Mon Mar 31 17:35:33 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |